QUICK READ: Bad headlines lead to clicks which in turn means more advertising revenue but besides scaring readers they are adding to the confusion around health. What’s real and what…
Author: Richard Meyer
Passionate, award-winning Marketing and Media Executive with an MBA and 15+ years success implementing cutting-edge strategies. Career highlights include driving development/launch of a groundbreaking e-Marketing branding initiative for Eli Lilly product Cialis that led to Website becoming #1 online pharma destination (and #1 in prescription conversions), increasing leads 30% and ROI 38% for $1B manufacturer Medtronic
On the pharma ecosystem
QUICK READ: There are a lot of patient-centered, hard-working people within the pharma industry. The problem is that there are way too many senior managers whose only goal is to…
The hypocrisy of pharma trade magazines
QUICK READ: Our industry is inundated with trade magazine pseudo awards that don’t mean a damn thing to the patients we serve. The dirty secret is that these trade magazines…
Will people line up for a COVID-19 vaccine?
QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. Personally I would want to know as…
COVID-19 and obesity is a lethal mix
QUICK READ: Obesity is associated with a higher risk of developing severe symptoms and complications of coronavirus disease, independent of other illnesses, such as cardiovascular disease. So why haven’t we…
Ten pharma digital marketing facts
QUICK READ: A reporter for a leading business magazine recently reached out to me and asked “what are Pharma product websites so bad?”. OK, maybe not all of them are…
COVID 19 vaccine means big money and greed
QUICK READ: Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive…
Launching a drug in a pandemic
QUICK READ: Prescribers are reviewing some of their favorite prescribed drugs and are open to learning about new drugs in terms of efficacy and patient outcomes but you had better…